EPS for SCYNEXIS, Inc. (SCYX) Expected At $-0.20

October 13, 2018 - By Adrian Erickson

Investors sentiment decreased to 0.93 in 2018 Q2. Its down 1.67, from 2.6 in 2018Q1. It dropped, as 8 investors sold SCYNEXIS, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 18.42 million shares or 0.71% more from 18.29 million shares in 2018Q1 were reported.
Rock Springs Cap Mgmt L P has invested 0.05% in SCYNEXIS, Inc. (NASDAQ:SCYX). Financial Bank Of New York Mellon owns 19,455 shares. Us Natl Bank De holds 0% in SCYNEXIS, Inc. (NASDAQ:SCYX) or 31,500 shares. Invesco Ltd has invested 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). Opus Point Mgmt Limited Liability Corporation holds 33,304 shares. Creative Planning holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 48,476 shares. Blackrock stated it has 180,751 shares or 0% of all its holdings. Moreover, Federated Inc Pa has 0.03% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 6.87M shares. Geode Management Llc holds 0% or 470,130 shares. Caxton Corporation reported 2.96M shares stake. Moreover, Spark Inv Mngmt Limited Co has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 40,000 shares. 266,803 were accumulated by Jpmorgan Chase Communications. Vanguard Grp reported 1.85M shares. Granite Point Cap Management L P holds 678,450 shares. Morgan Stanley reported 0% in SCYNEXIS, Inc. (NASDAQ:SCYX).

Since August 23, 2018, it had 2 insider buys, and 0 selling transactions for $41,140 activity. Angulo Gonzalez David bought $8,890 worth of stock.

Analysts expect SCYNEXIS, Inc. (NASDAQ:SCYX) to report $-0.20 EPS on November, 6.They anticipate $0.07 EPS change or 25.93 % from last quarter’s $-0.27 EPS. After having $-0.23 EPS previously, SCYNEXIS, Inc.’s analysts see -13.04 % EPS growth. The stock decreased 1.65% or $0.02 during the last trading session, reaching $1.19. About 129,793 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 41.01% since October 14, 2017 and is downtrending. It has underperformed by 56.63% the S&P500.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 4 analysts covering SCYNEXIS (NASDAQ:SCYX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SCYNEXIS had 4 analyst reports since May 7, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Friday, June 29 by Canaccord Genuity. The firm has “Buy” rating given on Monday, May 7 by H.C. Wainwright.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $55.95 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

SCYNEXIS, Inc. (NASDAQ:SCYX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News